

COVID-19 Products Scheme



June 2020

COVID-19 Products Scheme

As a direct response to the global COVID-19 pandemic, Ireland's new COVID-19 Products Scheme will allow for up to €200m in targeted State support.

Accelerate Research and Development

Upscale construction or upgrading of testing infrastructures

Fast-Track production capacity of products



COVID-19 Products Scheme

Purpose – To facilitate **upscaling** of testing and **fast track** expanded production into COVID-19 relevant products.

FOCUS AREAS & ACTIVITIES

Investment aid for testing and upscaling infrastructures for COVID-19 relevant products through Capital grants.

Note 6 Month completion Deadline



Investment aid for the production of COVID-19 relevant products through Capital grants.

Note 6 Month completion Deadline

- The construction or upgrade of testing and upscaling infrastructures required to develop, test and upscale, up to first industrial deployment prior to mass production, of COVID-19 relevant medicinal products (including vaccines) and treatments, their intermediates, active pharmaceutical ingredients and raw materials;
- Medical devices, hospital and medical equipment (including ventilators and protective clothing and equipment as well as diagnostic tools) and necessary raw materials; disinfectants and their intermediary products and raw chemical materials necessary for their production; as well as data collection/processing tools.
- Medicinal products (including vaccines) and treatments, their intermediates, active pharmaceutical ingredients and raw materials; medical devices, hospital and medical equipment (including ventilators, protective clothing and equipment as well as diagnostic tools) and necessary raw materials; disinfectants and their intermediary products and raw chemical materials necessary for their production; as well as data collection/processing tools.

COVID-19 Products Scheme

Purpose – To facilitate **accelerated** research and development into COVID-19 relevant products.

FOCUS AREAS & ACTIVITIES

Aid for COVID-19 relevant research and development through RD&I grants.

Note requirement to grant non-exclusive licenses to 3rd parties in EAA

- Research into COVID-19 vaccines, medicinal products and treatments, medical devices and hospital and medical equipment, disinfectants, and protective clothing and equipment, and into relevant process innovations for an efficient production of the required products.

Terms and Conditions



- Eligible expenditure from 1st of February 2020 is permitted.
- Projects must be approved and the grant agreement signed by 31st of December 2020.
- Research & Development commitment to grant non-exclusive licenses under market conditions to third parties in EAA states.
- Investment Aid Projects (non-R&D) must be complete within six months of the date of the grant agreement.
- Where the 6-month deadline is not met, the grant will reduce by 25% per month of delay, unless the delay is proven to be due to factors outside the control of the company.
- The company must not have been in financial difficulty on 31 of December 2019 (within the meaning of the General Block Exemption Regulation).
- All projects supported will be published on the European Commission web site.

For more information contact IDA Ireland  @IDAIreland  www.linkedin.com/company/ida-ireland www.idaireland.com